CareCloud (CCLD): +47% Surge in 30 Days on Record Earnings and AI Momentum
Key Takeaways
- CCLD stock surged +47% over the past 30 days, driven primarily by strong full-year 2025 earnings reported on March 12, featuring record net income and the first positive full-year EPS since IPO.
- Over the past quarter, shares gained +24%, supported by AI product launches, capital structure simplification, and revenue growth exceeding guidance.
- Key catalysts include robust Q4 revenue beat, entry into inpatient software via Medsphere acquisition, and positive cash flow generation amid healthcare IT demand.
- Recent volatility tied to cybersecurity disclosure and analyst commentary, but overall sentiment bolstered by profitability streak and growth outlook reaffirmation.
- Trading above 50-day moving average signals bullish short-term trend in healthcare technology sector.
Understanding CareCloud (CCLD) and Its Place in Healthcare IT
CareCloud, Inc. (CCLD) delivers cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) tailored for medical practices. The company's model centers on subscription platforms that handle practice management, patient engagement, and billing, with AI-driven tools adding efficiency.
In the crowded healthcare IT space, CareCloud stands out with its cost-effective offshore operations and generative AI features. Targeting small to mid-sized practices, its strengths—recurring revenue, seven straight quarters of GAAP profitability, and growing margins—have fueled the recent price gains. From what I see, investors are rewarding this transition from losses to steady earnings, especially as scalable tech gains traction in a digitizing healthcare sector.
CCLD Stock Performance: Breaking Down the Last 30 Days and Quarter
In the past 30 days, CCLD climbed from about $2.46 to $3.62, a +47% increase. The path was volatile but upward-trending, with a sharp post-earnings rally on March 12 (from $2.91 to near $3.81 highs by late March), then stabilizing around $3.50-$3.65 on high-volume days topping 900,000 shares.
Over the quarter, shares rose +24% from roughly $2.91 in early January to $3.62 today. This steady climb, with occasional dips, keeps it above the 50-day moving average of $2.85. A beta of 2.15 captures the sector's swings, while market cap sits at $154 million in a 52-week range of $1.14-$4.01.
The Key Drivers Behind CCLD's 30-Day Rally
The March 12 earnings stood out as the main driver, showing full-year 2025 revenue of $120.5 million (up 9% YoY), GAAP net income of $10.8 million (first positive full-year EPS of $0.10 since the 2014 IPO), and Q4 revenue of $34.4 million above estimates. Adjusted EBITDA reached 23% margins, backed by $28.6 million in operating cash flow.
Other news built on this: conversions of Preferred A stock streamlined the capital structure, while AI launches like the next-gen MAP App at the HFMA conference and the Medsphere acquisition opened inpatient EHR markets. Analyst comments on the AI strategy and profitability kept momentum going, even with a brief dip from Roth Capital's aircraft purchase note and a cybersecurity disclosure on health records. These elements tied straight to the surge, with post-earnings volume jumps pushing shares to 52-week highs near $3.81. I also checked this using Tickeron’s AI Screener to gauge how CCLD stacks up against industry peers.
What Fueled CCLD's +24% Quarterly Gain
The quarter's +24% advance reflected ongoing transformation themes: Q4 wrapped seven profitable quarters in a row, with revenue boosted by the Medsphere deal and AI enhancing RCM. Rising healthcare IT demand, driven by digitization mandates and cost pressures, aligns well with CareCloud's approach.
Broader supports included steady interest rates aiding growth stocks and rising institutional focus on the $28.6 million cash flow (up YoY). Offshore edges in Pakistan and Sri Lanka bolstered competitiveness, alongside Nasdaq compliance recovery. Overall, this led to outperformance versus peers, with 24% YTD gains topping the market.
Trending AI Robots: A Tool I Rely On
In my analysis, I often turn to Tickeron’s Trending AI Robots to spot top performers among hundreds of AI trading bots. These scan thousands of tickers using strategies like trend-following, mean reversion, and momentum, varying by timeframe, risk, win rate, Sharpe ratio, and drawdown. Curated by recent results, they provide backtested and live transparency that sharpens my stock reviews and trading ideas.
What's Next for CCLD: Key Forecast Factors to Track
Looking ahead, I'll be watching quarterly earnings for profitability continuity and progress toward 2026 revenue goals. Key areas include AI uptake, Medsphere integration, and RCM upgrades in a digitizing healthcare landscape.
Macro elements like interest rates, inflation on spending, and rules on interoperability matter too. Strategic moves—M&A, capital fixes, Nasdaq status—could shift things, alongside risks from cybersecurity, AI execution, and competition. Upside might come from upgrades or partnerships; this is important because sustained execution could reinforce the bullish trend.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
CCLD's Stochastic Oscillator remains in overbought zone for 3 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CCLD moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCLD as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CCLD broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CCLD just turned positive on July 28, 2026. Looking at past instances where CCLD's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
CCLD moved above its 50-day moving average on July 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CCLD crossed bullishly above the 50-day moving average on July 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CCLD advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 106 cases where CCLD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CCLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.131) is normal, around the industry mean (7.638). P/E Ratio (35.857) is within average values for comparable stocks, (46.808). CCLD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.726). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (0.832) is also within normal values, averaging (6.460).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical billing and transcription services
Industry ServicestotheHealthIndustry
Advertisement